ganirelix acetate

Also found in: Wikipedia.

ganirelix acetate

Orgalutran (CA) (UK)

Pharmacologic class: Gonadotropin-releasing hormone (GnRH) antagonist

Therapeutic class: Sex hormone

Pregnancy risk category X


Competitively blocks GnRH receptors on pituitary gonadotroph, suppressing secretion of gonadotropin and luteinizing hormone (LH) and thereby preventing ovulation


Prefilled syringe: 250 mcg/0.5 ml

Indications and dosages

To inhibit premature LH surges during controlled ovarian hyperstimulation

Adult women: 250 mcg subcutaneously daily during early to midfollicular phase


• Hypersensitivity to drug, its components, GnRH, or GnRH analogs
• Known or suspected pregnancy


Use cautiously in:
• GnRH sensitivity
• latex sensitivity (packaging contains natural rubber latex)
• breastfeeding patients.


Know that pregnancy must be excluded before therapy begins.
• Inject into abdomen (around navel) or upper thigh.
• Be aware that drug is given with follicle-stimulating hormone (FSH). After starting FSH on day 2 or 3 of menstrual cycle, patient receives ganirelix on morning of day 7 or 8 and continues this drug until adequate follicular response occurs. Then human chorionic gonadotropin is given and FSH and ganirelix are discontinued.

Adverse reactions

CNS: headache

GI: nausea, abdominal pain of GI tract origin

GU: abdominal pain of gynecologic origin, vaginal bleeding, ovarian hyperstimulation syndrome

Other: injection site reaction, fetal death


Drug-diagnostic tests.Hematocrit, total bilirubin: decreased values

Neutrophils: altered count (8.3/mm3 or greater)

Patient monitoring

Monitor patient for adverse effects, especially ovarian hyperstimulation.
• Monitor total bilirubin level and CBC with white cell differential.

Patient teaching

• Inform patient about possible adverse reactions.
• Teach patient about duration of treatment and required monitoring procedures.

Urge patient to tell prescriber if she is pregnant before starting drug.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.


An injectable synthetic decapeptide gonadotropin-releasing hormone (GnRH) antagonist used to inhibit premature LH surges in women undergoing controlled ovarian hyperstimulation in assisted reproduction.

Adverse effects
Gynaecologic pain, foetal death, headache, ovarian hyperstimulation syndrome, vaginal bleeding.
References in periodicals archive ?
Serono (virt-x SEO and NYSE: SRA) - In the first clinical trial to directly compare gonadotropin releasing hormone (GnRH) antagonists, patients using Cetrotide(R) (cetrorelix acetate for injection) required fewer injections compared to patients using Ganirelix Acetate (formerly known as Antagon(TM) Injection) to prevent premature ovulation during infertility treatment.
Cetrotide(R) offers patients a similar safety profile as well as similar efficacy compared to Ganirelix Acetate, but Cetrotide(R) has the added benefit of significantly fewer injections.
7%) required one injection while most of the patients who used Ganirelix Acetate (62.